Mediterranean Journal of Rheumatology最新文献

{"title":"Auguste François Chomel (1788-1858) and his Work on Rheumatism: Introducing Rheumatic Heart.","authors":"Georgia Fragou, George Philippidis, Panagiotis Georgakopoulos, Evaggelos Mavrommatis","doi":"10.31138/mjr.030223.afc","DOIUrl":"10.31138/mjr.030223.afc","url":null,"abstract":"<p><p>In the early 19^th century, Auguste François Chomel gathered the knowledge on rheumatism, systematised it, and published it in his majestic work <i>Pathologie</i> Générale. In his treatise, for the first time, rheumatic heart was discussed. Taking into account the opinions of the ancient Greek physicians, he had described the disease as an acute or chronic manifestation of the inflammation of the heart due to rheumatism. His publication rendered rheumatic heart an issue in vogue for his era, a disease being mentioned in all textbooks of the internal pathology.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"199-201"},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Factors Associated with Sarcopenia in Post-Menopausal Women with Rheumatoid Arthritis.","authors":"Dimitra Moschou, Michail Krikelis, Christos Georgakopoulos, Evangelia Mole, Efstathios Chronopoulos, Symeon Tournis, Clio Mavragani, Konstantinos Makris, Ismene Dontas, Susana Gazi","doi":"10.31138/mjr.260323.paf","DOIUrl":"10.31138/mjr.260323.paf","url":null,"abstract":"<p><strong>Objective/aim: </strong>To estimate the prevalence of sarcopenia in post-menopausal women with rheumatoid arthritis (RA) and to investigate possible correlation with disease parameters.</p><p><strong>Methods: </strong>Eighty post-menopausal women with RA and thirty post-menopausal controls were enrolled in this cross-sectional study. RA patients were further divided in two groups according to the existence of sarcopenia. Sarcopenia was defined according to EWGSOP-II recommendations and osteoporosis as a T-score≤-2.5 in femoral neck bone mineral density. Biomarkers of bone turnover were determined. RA disease activity was calculated using the DAS28-ESR score and inflammatory markers (ESR, CRP). Functionality was calculated with the HAQ-DI score and seropositivity was determined according to RF and anti-CCP antibodies.</p><p><strong>Results: </strong>Thirty-two post-menopausal women with RA (39%) met the EWGSOP-II criteria for sarcopenia. None of the control subjects was detected with sarcopenia (p<0.0001). All parameters that define sarcopenia were significantly lower in the RA group. Sarcopenic RA patients had significantly lower mean BMI (27.1 kg/m2 vs. 30.5 kg/m2, p=0.008), daily physical activity (IPAQ score) (1213 vs 2867, p<0.0001), mean skeletal muscle mass (ASMI) (5.2 kg/m2 vs 6.6 kg/m2, p<0.0001) and handgrip strength (13.7 kg vs 20.1 kg, p<0.0001). No differences were observed in disease parameters or in biomarkers of bone turnover. IGF-1 was the only parameter that differed between the sarcopenic and non-sarcopenic RA patients (90.1 ng/ml vs 112.8 ng/ml, p=0.024).</p><p><strong>Conclusion: </strong>Sarcopenia is more common in RA patients. Sarcopenic RA patients had lower BMI, IPAQ, ASMI and handgrip strength. IGF-1 was the only parameter that was significantly lower in sarcopenic RA patients.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 3","pages":"438-447"},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late-Presenting Eosinophilic Granulomatosis with Polyangiitis as Cause of Pulmonary Fibrosis: A Case-Based Review.","authors":"Juan Felipe Coronado-Sarmiento, Juan Pablo Coronado-López, Eduardo Tuta-Quintero, Claudia Marcela Mora, Viviana Mayor","doi":"10.31138/mjr.161023.lpe","DOIUrl":"10.31138/mjr.161023.lpe","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic granulomatosis with polyangiitis (eGPA) is a necrotising vasculitis of small and medium calibre vessels, which affects mostly patients in their fourth to sixth decade of life, and it is a very uncommon aetiology for pulmonary fibrosis.</p><p><strong>Clinical case: </strong>A Hispanic 72-year-old female patient presents with a history of lower extremities pain, paraesthesia, oedema, and occasional macroscopic haematuria. During her hospitalisation, the patient presents, and images showed findings compatible with pulmonary fibrosis and alveolar haemorrhage, which require a biopsy, establishing the diagnosis of an eGPA.</p><p><strong>Discussion: </strong>eGPA is a low-incidence autoimmune vasculitis, with a high number of phenotypes which explain the broad clinical spectrum, but recent advances has helped to understand the physiopathology and its link with other conditions like pulmonary fibrosis.</p><p><strong>Conclusion: </strong>Early diagnosis and management of this condition is mandatory because it is the only factor that change the outcome of the patients.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"172-178"},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of COVID-19 Vaccine in Patients with Rheumatic and Musculoskeletal Diseases.","authors":"Ali Abdulrahman Younis, Asal Adnan Ridha, Yasameen Abbas Humadi, Nizar Abdulateef Jassim, Nabaa Ihsan Awadh, Avin Maroof, Ali Mohammed Hussein Alqazzaz, Faiq I Gorial, Taha Ahmed Qaradaghi, Zahraa Salam Abdulzahra, Zainab A Mahmood, Noor Talal Yaseen, Duaa Nidhal AlIdrecy, Israa Talib Hakman, Saja Jabbar Tarfah, Adil Saudi Khudhair","doi":"10.31138/mjr.140223.sof","DOIUrl":"10.31138/mjr.140223.sof","url":null,"abstract":"<p><strong>Objectives: </strong>The main purpose of this study was to determine the frequency of COVID-19 vaccine side effects in patients with rheumatic diseases and to examine any potential associations with medications, disease type, or comorbidities.</p><p><strong>Methods: </strong>A multicentre cross-sectional study from rheumatology units in different hospitals in Iraq was carried out between 8^th of August 2021 and 4th of August 2022. Patients were eligible for inclusion if they have a rheumatic disease and have taken one or more doses of any COVID-19 vaccine.</p><p><strong>Results: </strong>A total of 661 (57.8% female, mean age 46.51± 12.97 years) patients with rheumatic illnesses who received the \"COVID-19\" vaccination were included in this study. Rheumatoid arthritis was the most frequent diagnostic group. The Pfizer vaccine was given to the majority of patients (74.6%), followed by Sinopharm (16.2%), and AstraZeneca (9.2%). Side effects were detected in 661(100%) and 528 (100%) patients following the first and second vaccination doses, respectively; among which the most frequent were injection site pain in 57.8% following the first dose and 47.6% after the second dose, followed by fatigue and fever. According to multivariate logistic regression models, age (B=-0.204, p = 0.000), had a significantly inverse correlation coefficient with the experience of greater side effects. Rheumatic disease flares reported in 9.9%, 10.3%, and 8.2% of patients who received the Pfizer, Sinopharm, and AstraZeneca vaccines, respectively.</p><p><strong>Conclusion: </strong>The \"COVID-19\" vaccination has a reassuring safety profile with no greater risk of adverse events in any specific illness or pharmacological therapy.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"123-133"},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep Quality is Poor in Rheumatoid Arthritis Patients and Correlates with Anxiety, Depression, and Poor Quality of Life.","authors":"Gurmeet Singh, Vijay Kumar","doi":"10.31138/mjr.221022.sqp","DOIUrl":"10.31138/mjr.221022.sqp","url":null,"abstract":"<p><strong>Objective: </strong>Sleep quality is poor in most rheumatoid arthritis (RA) patients. We planned this study to see the association of sleep quality with anxiety, depression, and quality of life (QOL) in Indian RA patients.</p><p><strong>Methods: </strong>One hundred twelve RA patients and 93 controls were included in this cross-sectional study. Sleep quality was assessed by Pittsburgh Sleep Quality Index (PSQI). Quality of life was assessed using the World Health Organisation Quality of Life (WHOQOL-BREF). Anxiety and depression were assessed using the hospital anxiety and depression scale (HADS). The disease activity was measured by Disease Activity Score for 28 joints with 3 variables. Functional disability was measured by using the Indian version of the Health Assessment Questionnaire (HAQ).</p><p><strong>Results: </strong>Poor sleep quality was seen in 103(92%) of the patients and 26(28%) controls (p<0.0001). RA patients had significantly higher PSQI scores as compared to the control group (10.8±3.7 vs.3.9±1.2, P<0.0001). Poor sleepers were more likely to be females (90% vs.0%, p = 0.02), and had longer disease duration (5.2±4.8 years vs. 2.8±2 years, p=0.01). Poor sleepers had more pain (VAS 42.2±23.6 mm vs.16.2±11.6 mm, p<0.001) and poor functional status (HAQ 1.2±0.5 vs. 0.6±0.4, p<0.01). There was a significant effect of the physical domain of WHOQOL-BREF, anxiety, and age on poor sleep quality.</p><p><strong>Conclusion: </strong>Poor sleep quality is seen in a majority of RA patients and correlates with anxiety, depression, and poor QOL. RA patients need to be routinely assessed for sleep quality and factors affecting poor sleep quality need to be addressed.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 3","pages":"423-431"},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of the Doctor-Patient Relationship on the Treatment Goal in Rheumatology.","authors":"Panagiota Tsatsani, Aspasia Goula, Maria-Aggeliki Stamouli, Sotiris Soulis","doi":"10.31138/mjr.110823.dpr","DOIUrl":"https://doi.org/10.31138/mjr.110823.dpr","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the perceptions of patients with rheumatic diseases about the doctor-patient relationship and the impact on their treatment and their quality of life.</p><p><strong>Methods: </strong>A quantitative study collecting data from patients with rheumatic diseases using the following tools: (a) the Doctor-Patient Relationship Assessment Questionnaire-16 (DoPRAQ-16), assessed the quality of doctor-patient relationship, (b) the Short Form 36 (SF-36) assessed the quality of life of patients, and (c) the Health Assessment Questionnaire (HAQ), assessed the functional ability of patients. From the statistical analysis, it appears that there is no linear correlation between the DoPRAQ-16 scales and the dimensions of the SF-36 Health Survey, except for the scale of negative emotions and the dimension of Physical Functioning. The nonparametric Kruskal-Wallis H test was performed to investigate the existence of statistically significant differences between the categories of duration of the relationship with the doctor to Physical Functioning, Physical Role, Emotional Role, and Social Functioning. The test was significant (p<0.05) for the dimensions of Body Role and Social Functioning.</p><p><strong>Conclusions: </strong>Patients with long term relationship with the doctor have better health quality in the dimension of Physical Role and Social Functioning compared to people whose relationship with the doctor lasts fewer years.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 2","pages":"283-290"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic Orbital Myositis Superseding Ocular Myasthenia.","authors":"Georges El Hasbani, Ali Tarhini, Razane Wehbe, Diamond Ghieh, Lama Farhat, Imad Uthman","doi":"10.31138/mjr.150523.eom","DOIUrl":"10.31138/mjr.150523.eom","url":null,"abstract":"<p><p>Various muscles can be involved in idiopathic eosinophilic myositis (IEM), with the ocular muscles being notably affected. Ocular eosinophilic myositis is a rare condition that typically affects the rectus muscles. A tissue biopsy stands as the gold standard for diagnosis. Different subtypes exist based on the extent of eosinophilic infiltration. Limited data is available about treatment, although glucocorticoids have shown successful outcomes. We present the case of a 60-year-old man who, a few years after being diagnosed with ocular myasthenia gravis, was diagnosed through a tissue biopsy with ocular eosinophilic myositis. Treatment with oral glucocorticoids significantly improved his symptoms.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"192-194"},"PeriodicalIF":0.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Drug Retention and Survival Rate of bDMARDs in Rheumatoid Arthritis: A Four-Year Real-Life Tunisian Experience.","authors":"Soumaya Boussaid, Houssem Tbini, Sonia Rekik, Saadaoui Khaled, Safa Rahmouni, Khaoula Zouaoui, Salem Riahi, Hela Sahli, Mohamed Elleuch","doi":"10.31138/mjr.090723.pof","DOIUrl":"10.31138/mjr.090723.pof","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to investigate the efficacy and tolerance of biologic disease-modifying anti-rheumatic drug (bDMARDs) in the current management of rheumatoid arthritis (RA) by identifying the retention time and survival rate of bDMARDs.</p><p><strong>Materials and methods: </strong>We conducted a retrospective cohort study including Tunisian patients initiating bDMARD treatment between 2016 and 2018 whose data were collected from the National Health Insurance Fund (NHIF). The NHIF is the national office which organises and centralises patients under bDMARDs from all over the country. Retention and survival rate of bDMARDs at 48 months were analysed using Kaplan-Meier survival curves and compared using the log-rank test. Survival factor analysis was performed using Cox regression.</p><p><strong>Results: </strong>Three hundred seventy-four patients, aged 55.5±12.5years [20-90], (87.2%women), were included. The mean duration of RA was 11.7±6.7 years [2-41]. The mean disease activity score (DAS)28 at initiation of the first bDMARD was 6.01±0.89 [5.37-6.5]. This first bDMARD induced low disease activity (LDA) in 55% of cases. Remission was observed in 28% of patients. The highest LDA and remission rates were observed with Tocilizumab (70.8% and 33.3% of cases, respectively). LDA and remission were achieved within a mean of 45 weeks [26-88] and 72 weeks [31-117] respectively. The 48-month first-line survival rate was 55.9%. Retention time was 41.7 months, 95%CI [39.47-43.91]. Presence of rheumatoid factors, co-prescription of methotrexate, and good initial therapeutic response were factors influencing better survival of bDMARDs (p<0.01). Glucocorticoid use predicted poorer survival (p<10-3). The first bDMARD was interrupted in 39% of cases. Ineffectiveness was the most common cause of treatment cessation (52.7%).</p><p><strong>Conclusion: </strong>This real-life study of the Tunisian population allowed us to establish the factors that can influence the survival and retention rates of bDMARDs.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 3","pages":"448-458"},"PeriodicalIF":0.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State of the Art Review on the Treatment of Psoriatic Disease.","authors":"Eleftherios Pelechas, Evripidis Kaltsonoudis, Michalis P Migkos, Nikolaos Koletsos, Panagiota G Karagianni, Alexandros A Drosos, Paraskevi V Voulgari","doi":"10.31138/mjr.040123.sot","DOIUrl":"10.31138/mjr.040123.sot","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is an inflammatory skin disease that in some cases is accompanied by systemic manifestations. Given the varied clinical manifestations, the term psoriatic disease probably better reflects the clinical picture of these patients.</p><p><strong>Literature review: </strong>In most cases, the skin lesions precede joint involvement as well as other potentially involved organs such as the intestine and the eye. Various immune-mediated cellular pathways such as that of TNFα, IL-23, IL-17 as well as other cytokines are involved in the pathophysiology of the psoriatic disease.</p><p><strong>Future insights: </strong>A better understanding of the way they interfere with our immune system has led to remarkably better disease control and outcomes. This review aims to highlight the newest treatments for psoriatic disease, which are expected to significantly reduce unmet needs and treatment gaps.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"66-72"},"PeriodicalIF":0.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rice Bodies in Rheumatoid Arthritis.","authors":"Ahmed Mougui, Imane El Bouchti","doi":"10.31138/mjr.310723.rbi","DOIUrl":"https://doi.org/10.31138/mjr.310723.rbi","url":null,"abstract":"","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 2","pages":"311"},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}